{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for monomethyl root_names_stdName in Standardized Name (approximate match)
4-Methoxyamphetamine (Para-methoxyamphetamine, PMA) is a synthetic drug chemically similar to the recreational drug 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and often replaces MDMA in tablets. Numerous cases of intoxication have been documented and fatal cases involving PMA have been described. PMA induces toxicity at lower doses than MDMA. Clinical symptoms specific to PMA poisoning include life-threatening hyperthermia, breathing difficulties, tachycardia, rhabdomyolysis, and acute renal failure. In the scarce studies conducted in laboratory animals, PMA has shown cardiovascular alterations in dogs, hyperthermia on a high ambient temperature, hallucinogen properties, and disruption of operant behavior in rats. A slight motor activity stimulation, lower than that induced by MDMA, has also been reported. The effects of PMA on brain neurotransmission are similar to those of MDMA, thus, PMA increases serotonin (5-hydroxytryptophan or 5-HT) release from the synaptic terminal and blocks its reuptake; it also acts upon noradrenergic and dopaminergic terminals but in a lesser proportion, and can also delay the metabolism of these monoamines by inhibition of monoamine oxidase (MAO)
Status:
US Previously Marketed
Source:
HISTADYL METHAPYRILENE by LILLY
(1961)
Source URL:
First approved in 1947
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Methapyrilene is an antihistamine and anticholinergic of the pyridine chemical class which was developed in the early 1950s. It was sold under the trade names Co-Pyronil and Histadyl EC. It has relatively strong sedative effects, to the extent that its primary use was as a medication for insomnia rather than for its antihistamine action. Together with scopolamine, it was the main ingredient in Sominex, Nytol, and Sleep-Eze. It also provided the sedative component of Excedrin PM. Manufacturers voluntarily withdrew methapyrilineb drug products from the market in May and June 1979, when methapyrilene was demonstrated to cause liver cancer in rats when given chronically.
Status:
US Previously Marketed
Source:
Monomestrol by Wallace & Tiernan
(1943)
Source URL:
First approved in 1943
Source:
Monomestrol by Wallace & Tiernan
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Previously Marketed
Source:
Guaiacol
(1892)
Source URL:
First marketed in 1892
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Guaiacol is a naturally occurring organic compound first isolated by Otto Unverdorben in 1826. Although it is biosynthesized by a variety of organisms, this yellowish aromatic oil is usually derived from guaiacum or wood creosote. Guaiacol is used as a reducing co-substrate for COX reactions. It is mainly used as expectorant, antiseptic. It is used as cough suppressant, it is an ingredient of Pulmo Bailly (UK). Pulmo Bailly Cough Expectorant is indicated for relief for cough symptoms that are associated with a flu, cold, or other infection. It contains active ingredients, Codeine and Guajacol, which reduce discomfort and the urge to cough. Each 5 ml tablespoon of Pulmo Bailly contains 75 mg guaiacol and 7 mg codeine.
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2014
Source:
21 CFR 358A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Diethylene glycol monomethyl ether is a ether-alcohol derivative. The ether being relatively unreactive. Flammable and/or toxic gases are generated by the combination of alcohols with alkali metals, nitrides, and strong reducing agents. They react with oxoacids and carboxylic acids to form esters plus water. Oxidizing agents convert alcohols to aldehydes or ketones. Alcohols exhibit both weak acid and weak base behavior. They may initiate the polymerization of isocyanates and epoxides. Diethylene glycol monomethyl ether (DEGME) is sold by Dow
under the tradename Methyl CARBITOL™ solvent. DEGME is an ethylene-series or E-series
glycol ether. It is primarily used as a de-icing additive for aviation fuel.